{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:59:18Z","timestamp":1789016358740,"version":"build-2803163510"},"reference-count":77,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974003, 81500168, 81974007"],"award-info":[{"award-number":["81974003, 81500168, 81974007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Currently, the graft-versus-host disease (GVHD) prophylaxis consists of an immunosuppressive therapy mainly based on antithymocyte globulin (ATG) or post-transplant cyclophosphamide (PTCy). GVHD remains a major complication and limitation to successful allogeneic haploidentical hematopoietic stem cell transplantation (haplo\u2010HSCT). We modified the ATG-based GVHD prophylaxis with the addition of basiliximab in the setting of haplo-HSCT and attempted to explore the appropriate dosages. We conducted a retrospective analysis of 239 patients with intermediate- or high-risk hematologic malignancies who received haplo-HSCT with unmanipulated peripheral blood stem cells combined or not with bone marrow. All patients received the same GVHD prophylaxis consisting of the combination of methotrexate, cyclosporine or tacrolimus, mycofenolate-mofetil, and basiliximab with different doses of ATG (5-9mg\/kg). With a median time of 11 days (range, 7-40 days), the rate of neutrophil engraftment was 96.65%. The 100-day cumulative incidences (CIs) of grade II\u2013IV and III\u2013IV aGVHD were 15.8 \u00b1 2.5% and 5.0 \u00b1 1.5%, while the 2-year CIs of total cGVHD and extensive cGVHD were 9.8 \u00b1 2.2% and 4.1 \u00b1 1.5%, respectively. The 3-year CIs of treatment-related mortality (TRM), relapse, overall survival (OS), and disease-free survival (DFS) were 14.6 \u00b1 2.6%, 28.1 \u00b1 3.4%, 60.9 \u00b1 3.4%, 57.3 \u00b1 3.4%, respectively. Furthermore, the impact of the reduction of the ATG dose to 6 mg\/kg or less in combination with basiliximab on GVHD prevention and transplant outcomes among patients was analyzed. Compared to higher dose of ATG(&amp;gt;6mg\/kg), lower dose of ATG (\u22646mg\/kg) was associated with a significant reduced risk of CMV viremia (52.38% <jats:italic>vs<\/jats:italic> 79.35%, <jats:italic>P<\/jats:italic>&amp;lt;0.001), while the incidences of aGVHD and cGVHD were similar between the two dose levels. No significant effect was found with regard to the risk of relapse, TRM, and OS. ATG combined with basiliximab could prevent GVHD efficiently and safely. The optimal scheme of using this combined regimen of ATG and basiliximab is that administration of lower dose ATG (\u22646mg\/kg), which seems to be more appropriate for balancing infection control and GVHD prophylaxis.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1017850","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T06:17:00Z","timestamp":1668493020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Lower dose of ATG combined with basiliximab for haploidentical hematopoietic stem cell transplantation is associated with effective control of GVHD and less CMV viremia"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhenli","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Teng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2012.1.230","article-title":"Haploidentical transplantation for hematologic malignancies: where do we stand","volume":"2012","author":"Fuchs","year":"2012","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.312","article-title":"Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.blre.2014.09.009","article-title":"\"No donor\"? consider a haploidentical transplant","volume":"29","author":"Ciurea","year":"2015","journal-title":"Blood Rev"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-627786","article-title":"Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27761","article-title":"Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center","volume":"119","author":"Wang","year":"2013","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.07.008","article-title":"Reduced-intensity conditioning and dual T lymphocyte suppression with antithymocyte globulin and post-transplant cyclophosphamide as graft-versus-Host disease prophylaxis in haploidentical hematopoietic stem cell transplants for hematological malignancies","volume":"24","author":"Law","year":"2018","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2016.166","article-title":"Haploidentical, unmanipulated G-CSF-primed peripheral blood stem cell transplantation for high-risk hematologic malignancies: an update","volume":"51","author":"Huang","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.01.004","article-title":"Haploidentical stem cell transplantation: anti-thymocyte globulin-based experience","volume":"53","author":"Chang","year":"2016","journal-title":"Semin Hematol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2012.09.005","article-title":"Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation","volume":"39","author":"Luznik","year":"2012","journal-title":"Semin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2016.01.005","article-title":"Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide","volume":"53","author":"Robinson","year":"2016","journal-title":"Semin Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151779","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant","volume":"102","author":"Ruggeri","year":"2017","journal-title":"Haematologica"},{"key":"B13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","article-title":"Antilymphocyte globulin for prevention of chronic graft-versus-Host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"New Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.05.020","article-title":"Impact of donor and recipient cytomegalovirus serostatus on outcomes of antithymocyte globulin-conditioned hematopoietic cell transplantation","volume":"22","author":"Kalra","year":"2016","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"New Engl J Med"},{"key":"B17","article-title":"Anti-interleukin-2 receptor antibodies-basiliximab and daclizumab-for the prevention of acute rejection in renal transplantation","volume":"3","author":"Sageshima","year":"2009","journal-title":"Biologics"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.healun.2007.05.002","article-title":"Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy","volume":"26","author":"Mattei","year":"2007","journal-title":"J Heart Lung Transplant Off Publ Int Soc Heart Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1277307","article-title":"Combining therapeutic antibodies using basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease: A multi-center prospective study","volume":"6","author":"Tan","year":"2017","journal-title":"Oncoimmunology"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.749266","article-title":"Meta-analysis of interleukin-2 receptor antagonists as the treatment for steroid-refractory acute graft\u2013host disease","volume":"12","author":"Shen","year":"2021","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.916442","article-title":"Immune reconstitution of patients who recovered from steroid-refractory acute graft-Versus-Host disease after basiliximab treatment","volume":"12","author":"Deng","year":"2022","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26568","article-title":"Salvage therapy with basiliximab and etanercept for severe steroid-refractory acute graft-versus-host disease","volume":"97","author":"Freyer","year":"2022","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26475","article-title":"Basiliximab for steroid-refractory acute graft-versus-host disease: A real-world analysis","volume":"97","author":"Mo","year":"2022","journal-title":"Am J Hematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.2010.485187","article-title":"Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation","volume":"10","author":"Campara","year":"2010","journal-title":"Expert Opin Biol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.12.624","article-title":"CD25 blockade delays regulatory T cell reconstitution and does not prevent graft-versus-Host disease after allogeneic hematopoietic cell transplantation","volume":"23","author":"Locke","year":"2017","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2011.09.005","article-title":"Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation","volume":"18","author":"Fang","year":"2012","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bmt.1705046","article-title":"Anti-CD25 monoclonal antibody (basiliximab) for prevention of graft-versus-host disease after haploidentical bone marrow transplantation for hematological malignancies","volume":"36","author":"Ji","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2017.100","article-title":"Idarubicin-intensified haploidentical HSCT with GvHD prophylaxis of ATG and basiliximab provides comparable results to sibling donors in high-risk acute leukemia","volume":"52","author":"Zhang","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.91","article-title":"Haploidentical, G-CSF-primed, unmanipulated bone marrow transplantation for patients with high-risk hematological malignancies: an update","author":"Arcese","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-453399","article-title":"Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies","volume":"121","author":"Di Bartolomeo","year":"2013","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.624225","article-title":"Haploidentical hematopoietic stem cell transplantation in hematologic malignancies with G-CSF mobilized bone marrow plus peripheral blood stem cells grafts without T cell depletion: a single center report of 29 cases","volume":"53","author":"Wang","year":"2012","journal-title":"Leukemia lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0081-x","article-title":"Haploidentical hematopoietic stem cell transplantation following myeloablative conditioning regimens in hematologic diseases with G-CSF-mobilized peripheral blood stem cells grafts without T cell depletion: a single center report of 38 cases","volume":"31","author":"Lu","year":"2014","journal-title":"Med Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.08.015","article-title":"Comparison of outcomes of idarubicin intensified TBI-CY and traditional TBI-CY conditioning regimen for high-risk acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation: A single center experience","volume":"39","author":"Wu","year":"2015","journal-title":"Leukemia Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.04.014","article-title":"Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective comparative study","volume":"46","author":"Fang","year":"2016","journal-title":"Leukemia Res"},{"key":"B35","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B37","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.bbmt.2018.07.021","article-title":"Idarubicin-intensified hematopoietic cell transplantation improves relapse and survival of high-risk acute leukemia patients with minimal residual disease","volume":"25","author":"Zhang","year":"2019","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.305","article-title":"Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission","volume":"51","author":"Ruggeri","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"B39","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.bbmt.2018.01.008","article-title":"Proceedings from the fourth haploidentical stem cell transplantation symposium (HAPLO2016), San Diego, California, December 1, 2016","volume":"24","author":"Al Malki","year":"2018","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148510","article-title":"Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the acute leukemia working party of the European society for blood and marrow transplantation","volume":"102","author":"Baron","year":"2017","journal-title":"Haematologica"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0382-3","article-title":"Low-dose anti-thymocyte globulin plus low-dose posttransplant cyclophosphamide as graft-versus-host disease prophylaxis in haploidentical peripheral blood stem cell transplantation combined with unrelated cord blood for patients with hematologic malignancies: a prospective, phase II study","volume":"54","author":"Yang","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"B43","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-019-0781-y","article-title":"Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01569-x","article-title":"Disease-specific impact of anti-thymocyte globulin in allogeneic hematopoietic cell transplantation: a nationwide retrospective study on behalf of the JSTCT, transplant complications working group","volume":"57","author":"Fuji","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003779","article-title":"A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation","volume":"5","author":"Bejanyan","year":"2021","journal-title":"Blood Adv"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.844937","article-title":"Decitabine-intensified modified Busulfan\/Cyclophosphamide conditioning regimen improves survival in acute myeloid leukemia patients undergoing related donor hematopoietic stem cell transplantation: A propensity score matched analysis","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-Cell-Replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/bmt.2013.223","article-title":"HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies","volume":"49","author":"Zhang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B50","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13045-016-0248-3","article-title":"Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT","volume":"9","author":"Rubio","year":"2016","journal-title":"J Hematol Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017006429","article-title":"The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis","volume":"1","author":"Lorentino","year":"2017","journal-title":"Blood Adv"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-019-9594-7","article-title":"Comparison of the clinical outcomes of hematologic malignancies after myeloablative haploidentical transplantation with G-CSF\/ATG and posttransplant cyclophosphamide: results from the Chinese bone marrow transplantation registry group (CBMTRG)","volume":"63","author":"Tang","year":"2020","journal-title":"Sci China Life Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.93","article-title":"Unmanipulated haploidentical bone marrow transplantation and post-transplant cyclophosphamide for hematologic malignanices following a myeloablative conditioning: an update","author":"Bacigalupo","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.2991\/chi.d.190316.003","article-title":"Safety and efficacy of haploidentical peripheral blood stem cell transplantation for myeloid malignancies using post-transplantation cyclophosphamide and anti-thymocyte globulin as graft\u2013host disease prophylaxis","volume":"1","author":"Salas","year":"2019","journal-title":"Clin Hematol Int"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.247296","article-title":"Post-transplant cyclophosphamide versus anti-thymocyte globulin for graft-versus-host disease prevention in haploidentical transplantation for adult acute lymphoblastic leukemia","volume":"106","author":"Nagler","year":"2021","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"crossref","DOI":"10.1007\/BF02982797","article-title":"The association of HLA antigen and GVHD in allogeneic hemopoietic stem cell transplantation with histocompatible sibling donor: a single-center experience in Korea","volume":"76","author":"Kim","year":"2002","journal-title":"Int J Hematol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.265769","article-title":"Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study","volume":"107","author":"Greinix","year":"2022","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.05.025","article-title":"Reduced-intensity conditioning with busulfan, fludarabine, and antithymocyte globulin for hematopoietic cell transplantation from unrelated or haploidentical family donors in patients with acute myeloid leukemia in remission","volume":"23","author":"Lee","year":"2017","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01047-2","article-title":"Low dose anti-thymocyte globulin with low dose posttransplant cyclophosphamide (low dose ATG\/PTCy) can reduce the risk of graft-versus-host disease as compared with standard-dose anti-thymocyte globulin in haploidentical peripheral hematopoietic stem cell transplantation combined with unrelated cord blood","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2423-y","article-title":"Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings","volume":"94","author":"Tischer","year":"2015","journal-title":"Ann Hematol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"New Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"New Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S79131","article-title":"Letermovir and inhibitors of the terminase complex: a promising new class of investigational antiviral drugs against human cytomegalovirus","volume":"8","author":"Melendez","year":"2015","journal-title":"Infect Drug Resist"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-623991","article-title":"Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide","volume":"125","author":"McCurdy","year":"2015","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2015.04.025","article-title":"Post-transplantation cyclophosphamide and sirolimus after haploidentical hematopoietic stem cell transplantation using a treosulfan-based myeloablative conditioning and peripheral blood stem cells","volume":"21","author":"Cieri","year":"2015","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/cancers14041097","article-title":"Outcomes of different haploidentical transplantation strategies from the Taiwan blood and marrow transplantation registry","volume":"14","author":"Tsai","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.2217\/imt.15.128","article-title":"Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations","volume":"8","author":"Nishihori","year":"2016","journal-title":"Immunotherapy"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2015.148","article-title":"Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation","volume":"50","author":"Binkert","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"B74","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1186\/s12967-015-0748-x","article-title":"Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation","volume":"13","author":"Liu","year":"2015","journal-title":"J Transl Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.336","article-title":"A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia","volume":"29","author":"Piemontese","year":"2015","journal-title":"Leukemia"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.11.025","article-title":"Treatment of acute leukemia with unmanipulated HLA-mismatched\/haploidentical blood and bone marrow transplantation","volume":"15","author":"Huang","year":"2009","journal-title":"Biol Blood marrow Transplant J Am Soc Blood Marrow Transplant"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T06:17:05Z","timestamp":1668493025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1017850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":77,"alternative-id":["10.3389\/fimmu.2022.1017850"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1017850","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"1017850"}}